On March 9, 2022 Portage Biotech Inc. (NASDAQ: PRTG) ("Portage" or the "Company"), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, and Stimunity, an early-stage biotech company focused on the development of a unique STING agonist based on virus-like particles, reported data from a collaboration on a STINGactivating therapy, PORT-5 (STI-001) will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) 2022 Annual Meeting taking place April 8-13, 2022, in New Orleans, Louisiana (Press release, Portage Biotech, MAR 9, 2022, View Source [SID1234609762]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The stimulator of interferon genes (STING) pathway is a well-recognized immune-boosting pathway and has long been an area of interest in cancer treatment, but STING-activating therapies have historically been limited in clinical trials due to delivery challenges," said Dr. Ian Walters, chief executive officer of Portage. "We are grateful that the scientific committee found the research on our systemically delivered STING-based therapy, PORT-5, to be highly significant and timely to be included in the late-breaking session for AACR (Free AACR Whitepaper) and look forward to sharing further updates in the coming months."

Presentation Details
Abstract Title: Cellular selectivity of STING stimulation determines priming of anti-tumor T cell responses
Abstract Number: 7829
Presenter: Bakhos Jneid, Institut Curie
Session Title: Late-Breaking Research: Experimental and Molecular Therapeutics 2
Session Date/Time: April 13, 2022, 9:00am – 12:30pm CT
Location: Poster Section 16

On March 9, 2022 Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibition of SEMA4D, reported that it has been selected for poster presentation related to the phase 1b segment of its KEYNOTE-B84 study of pepinemab in combination with KEYTRUDA (pembrolizumab) in patients with recurrent or metastatic head and neck cancer during the upcoming 2022 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Meetings (2022 AACR (Free AACR Whitepaper)), taking place from April 8th to April 13th in New Orleans via in person and virtual attendance (Press release, Vaccinex, MAR 9, 2022, View Source [SID1234609761]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details are shown below:
Abstract title: Phase 1/2 study of pepinemab, an inhibitor of semaphorin 4D, in combination with pembrolizumab as first-line treatment of recurrent or metastatic head and neck cancer (KEYNOTE B84)
Presenter: Terrence Fisher, PhD, VP Clinical Science
Abstract: CT111
Session: Phase II Clinical Trials 1
Date and Time: Monday Apr 11, 2022 9:00 AM – 12:30 PM, CST
Venue: New Orleans Ernest N. Morial Convention Center, New Orleans, LA, USA

Vaccinex has global commercial and development rights to pepinemab, and is sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of Merck and Co, Inc. Kenilworth, NJ, USA. Additional information about the study is available at: clinicaltrials.gov link.

KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., Kenilworth, NJ, USA.

About Pepinemab
Pepinemab is a humanized IgG4 monoclonal antibody that inhibits SEMA4D, which regulates tumor immunity. Preclinical and clinical data show that pepinemab promotes infiltration/activation of dendritic cells/ CD8+ T-cells and reverses immunosuppression within the tumor.

Results of a Phase 1b/2 study to evaluate the combination of pepinemab with checkpoint inhibitor, BAVENCIO, avelumab (Merck KGaA) were presented at ASCO (Free ASCO Whitepaper) 2020 and were highlighted in the July 2021 publication of Clinical Cancer Research. Vaccinex reported that results of the Phase 1b/2 CLASSICAL-Lung trial showed a 25-33% Overall Response Rate (ORR) for patients with difficult to treat PD-L1 low/negative tumors treated with combination therapy and highlighted reason to anticipate a potentially greater response in cancer indications with higher levels of myeloid suppressor cells including R/M HNSCC. The study report also indicated that pepinemab did not increase immune-related toxicities of BAVENCIO but increased penetration of cytotoxic T cells. The publication is available electronically at: Clinical Cancer Research.

On March 9, 2022 Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, reported that management will be presenting a corporate overview and participating in 1-on-1 meetings in the 32nd Annual Oppenheimer Healthcare Conference taking place virtually on March 16th, 2022 (Press release, Infinity Pharmaceuticals, MAR 9, 2022, View Source [SID1234609760]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

32nd Annual Oppenheimer Healthcare Conference (virtual)

Date: March 16th, 2022

Time: 2:40pm – 3:10pm ET

Speaker: Adelene Perkins, Chief Executive Officer

Format: Company Presentation

Webcast Registration Link.

*a replay will be available following the presentation for 90 days

On March 9, 2022 Prelude Therapeutics Incorporated (Nasdaq: PRLD) a clinical-stage precision oncology company, reported that Jane Huang, M.D., has been appointed to the newly created position of President and Chief Medical Officer, effective on April 4, 2022 (Press release, Prelude Therapeutics, MAR 9, 2022, View Source [SID1234609759]). Dr. Huang is currently Chief Medical Officer, Hematology, at BeiGene, Ltd., a global, science-driven biotechnology company developing oral small molecules and monoclonal antibodies for cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to announce that Dr. Huang will be joining Prelude. Jane’s deep experience in oncology drug development and her strategic leadership throughout the lifecycle of multiple products resulting in successful global regulatory approvals will be of great value to Prelude," stated Kris Vaddi, Ph.D., Chief Executive Officer of Prelude.

Dr. Vaddi added, "With multiple distinct precision oncology programs underway, our growing pipeline offers tremendous promise. I am confident in Jane’s ability to build and lead high-performing cross-functional clinical development teams, and her strong relationships and recognized leadership within the cancer research community will be instrumental in achieving our goals to rapidly advance compounds through proof-of-concept and into potential registration trials."

"I am impressed by the strong execution of the Prelude R&D team and its ability to bring multiple proprietary and potentially best-in-class small molecule compounds forward. Their strategic selection of clinically relevant targets involved in many underserved cancers is equally impressive. This level of performance gives me confidence that Prelude is uniquely resourced to make a meaningful difference in the lives of cancer patients," stated Dr. Huang.

Most recently, Dr. Huang served as Chief Medical Officer of Hematology at BeiGene, Ltd. where she created a global development organization encompassing clinical pharmacology to global product safety and had strategic oversight of the development of five hematology medicines. During her tenure with BeiGene, she oversaw the approval of zanubrutinib in three diseases spanning more than 45 countries and was responsible for the first approval of tislelizumab in Hodgkin’s lymphoma. Prior to joining BeiGene in 2016, Dr. Huang served as Vice President, Clinical Development at Acerta Pharma, where she oversaw global clinical development of the BTK inhibitor, acalabrutinib. Prior to this, she worked at Genentech, where she played a leading role in drug development programs for multiple therapies throughout all stages of development, including, Rituxan, Avastin, Kadcyla, Venclexta and Gazyva. She is board certified in hematology, oncology, and internal medicine and is Adjunct Clinical Assistant Professor at Stanford University. Dr. Huang was recently named one of the 20 most influential women in biopharma R&D by Endpoints News.

On March 9, 2022 Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, reported that two posters have been accepted for presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, which is being held April 8-13, 2022 at the Ernest N. Morial Convention Center in New Orleans, Louisiana (Press release, Shattuck Labs, MAR 9, 2022, View Source [SID1234609758]). The first poster will highlight preclinical data from the company’s GADLEN platform, while the second will highlight preclinical data from SL-9258 (TIGIT-Fc-LIGHT), derived from the company’s ARC platform, demonstrating its ability to broaden the activity of checkpoint inhibitors through targeted myeloid cell and effector lymphocyte activation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details

Title: Bispecific gamma delta T cell engagers containing butyrophilin 2A1/3A1 heterodimeric fusion protein efficiently activate Vg9Vd2 T cells and promote tumor cell killing
Presenter: Dr. Anne Lai, Ph.D., Principal Scientist, Shattuck
Session: Immunology – Immunomodulatory Agents and Interventions 2
Date/Time: Tuesday, April 12, 2022, 1:30 p.m. to 5:00 p.m. ET
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 37
Abstract Number: 3514

Title: LIGHT (TNFSF14) costimulation with TIGIT blockade broadens the activity of checkpoint inhibitors (CPIs) into CPI refractory and resistant tumors through targeted myeloid cell and effector lymphocyte activation
Presenters: Dr. George Fromm, Ph.D., Vice President of Research and Development, Shattuck, and Kyung Jin Yoo, Research Associate, Shattuck
Session: Immunology – Combination Immunotherapies 2
Date/Time: Wednesday, April 13, 2022, 9:00 a.m. to 12:30 p.m. ET
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 37
Abstract Number: 4214

Additional meeting information can be found on the AACR (Free AACR Whitepaper) website, View Source The posters will be available under the Events & Presentations section of the Company’s website shortly after the event.